Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.

被引：2
|
作者：
Vilbert, Maysa
Priantti, Jonathan N.
Madeira, Thiago
Moraes, Francisco Cezar A.
Tojjari, Alireza
Sahin, Ibrahim Halil
Cavalcante, Ludimila
Saeed, Anwaar
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Fed Univ Amazonas UFAM, Manaus, AM, Brazil
[3] Fed Univ Minas Gerais UFMG, Belo Horizonte, MG, Brazil
[4] Fed Univ Para UFPA, Belem, PA, Brazil
[5] Novant Hlth Canc Inst, Charlotte, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-566-9718-9794; 261-492-3532-2370-7650-2700; 283-424-6846-271-2644; 283-2494; 130-540-543-4790; 261-492-2769; 3282-3306-2666-6279; 7; 4; 3; 2; 1614; 1597; 8; 1; 38092-27449; 38092-20072; 6;
D O I：
10.1200/JCO.2024.42.3_suppl.366
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [21] First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis
    Liang, Xueyan
    Meng, Mingyu
    Qin, Shiran
    Chen, Xiaoyu
    Li, Yan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [22] Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China
    Liu, Shixian
    Dou, Lei
    Li, Shunping
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [23] Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China
    Liu, Shixian
    Jiang, Nana
    Dou, Lei
    Li, Shunping
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [24] Anti PD-1 Checkpoint Inhibitor As a First-Line Treatment for Advanced Cutaneous Squamous Cell Carcinoma
    Bopota, Katerina
    Donnelly, Oliver
    Borumandi, Farzad
    JOURNAL OF CRANIOFACIAL SURGERY, 2023, 34 (03) : E247 - E249
  • [25] Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy
    Li, Lingling
    Pi, Chenghui
    Yan, Xin
    Lu, Jiangyue
    Yang, Xuhui
    Wang, Chunyu
    Li, Xiaoyan
    Zhang, Sujie
    Zhang, Zhibo
    Sun, Yi
    Hu, Yi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [26] Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More
    Zheng, Zhiwei
    Lin, Jingrong
    Zhu, Huide
    Cai, Hongfu
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [27] Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma
    Loo, Kimberly
    Daud, Adil
    IMMUNOTHERAPY, 2016, 8 (07) : 775 - 784
  • [28] Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
    Ikeda, Sadakatsu
    Goodman, Aaron M.
    Cohen, Philip R.
    Jensen, Taylor J.
    Ellison, Christopher K.
    Frampton, Garrett
    Miller, Vincent
    Patel, Sandip P.
    Kurzrock, Razelle
    NPJ GENOMIC MEDICINE, 2016, 1
  • [29] Comparison analysis of PD-1/PD-L1 inhibitors plus lenvatinib or gemcitabine/cisplatin as first-line treatment for patients with advanced intrahepatic cholangiocarcinoma
    Huang, Jia-Xin
    Liu, Bo
    Li, Yu
    Li, Xi
    Ding, Li-Juan
    Wang, Nan-Ya
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
    Sadakatsu Ikeda
    Aaron M Goodman
    Philip R Cohen
    Taylor J Jensen
    Christopher K Ellison
    Garrett Frampton
    Vincent Miller
    Sandip P Patel
    Razelle Kurzrock
    npj Genomic Medicine, 1
12345